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Quality of Life Analysis of a Radiation Dose–Escalation
Study of Patients With Non–Small-Cell Lung Cancer
A Secondary Analysis of the Radiation Therapy Oncology
Group 0617 Randomized Clinical Trial
Benjamin Movsas, MD; Chen Hu, PhD; Jeffrey Sloan, PhD, HSR; Jeffrey Bradley, MD; Ritsuko Komaki, MD; Gregory Masters, MD; Vivek Kavadi, MD;
Samir Narayan, MD; Jeff Michalski, MD; Douglas W. Johnson, MD; Christopher Koprowski, MD; Walter J. Curran Jr, MD; Yolanda I. Garces, MD;
Rakesh Gaur, MD; Raymond B. Wynn, MD; John Schallenkamp, MD; Daphna Y. Gelblum, MD; Robert M. MacRae, MD; Rebecca Paulus, BS; Hak Choy, MD

IMPORTANCE A recent randomized radiation dose–escalation trial in unresectable stage III

non–small-cell lung cancer (NSCLC) (Radiation Therapy Oncology Group [RTOG] 0617)
showed a lower survival rate in the high-dose radiation therapy (RT) arm (74 Gy) than in the
low-dose arm (60 Gy) with concurrent chemotherapy.
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OBJECTIVE The primary QOL hypothesis predicted a clinically meaningful decline in quality of
life (QOL) via the Functional Assessment of Cancer Therapy (FACT)–Lung Cancer Subscale
(LCS) in the high-dose RT arm at 3 months.
DESIGN, SETTING, AND PATIENTS The RTOG 0617 trial was a randomized phase 3 study
(conducted from November 2007 to November 2011) in stage III NSCLC using a 2 × 2 factorial
design and stratified by histology, positron emission tomography staging, performance
status, and irradiation technique (3-dimensional conformal RT [3D-CRT] vs intensitymodulated RT [IMRT]). A total of 185 institutions in the United States and Canada took part.
Of 424 eligible patients with stage III NSCLC randomized, 360 (85%) consented to QOL
evaluation, of whom 313 (88%) completed baseline QOL assessments.
INTERVENTION Treatment with 74-Gy vs 60-Gy RT with concurrent and consolidation

carboplatin/paclitaxel with or without cetuximab.
MAIN OUTCOMES AND MEASURES The QOL data were collected prospectively via FACT Trial
Outcome Index (FACT-TOI), calculated as the sum of the following measures: Physical Well
Being (PWB), Functional Well Being (FWB), and the LCS. Data are presented at baseline and 3
and 12 months via minimal clinically meaningful changes of 2 points or more for PWB, FWB,
and LCS or 5 points or more for TOI.
RESULTS Of the 313 patients who completed baseline QOL assessments, 219 patients (70%)
completed the 3-month QOL assessments, and 137 of the living patients (57%) completed the
12-month assessment. Patient demographics and baseline QOL scores were comparable
between the 74-Gy and 60-Gy arms. Significantly more patients in the 74-Gy arm than in the
60-Gy arm had clinically meaningful decline in FACT-LCS at 3 months (45% vs 30%; P = .02).
At 12 months, fewer patients who received IMRT (vs 3D-CRT) had clinically meaningful
decline in FACT-LCS (21% vs 46%; P = .003). Baseline FACT-TOI was associated with overall
survival in multivariate analysis.
CONCLUSIONS AND RELEVANCE Despite few differences in clinician-reported toxic effects
between treatment arms, QOL analysis demonstrated a clinically meaningful decline in QOL
in the 74-Gy arm at 3 months, confirming the primary QOL hypothesis. Baseline QOL was an
independent prognostic factor for survival.
TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00533949
JAMA Oncol. 2016;2(3):359-367. doi:10.1001/jamaoncol.2015.3969
Published online November 25, 2015.
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T

he Radiation Therapy Oncology Group (RTOG) 0617
study1 was an intergroup phase 3 trial that randomized
patients with unresectable stage III non–small-cell lung
cancer (NSCLC) to 1 of 4 treatment arms in a 2 × 2 factorial design: 60-Gy radiation therapy (RT) (standard dose) vs 74-Gy
RT (high dose) with concurrent and consolidation chemotherapy with or without cetuximab. This study asked whether
or not RT dose escalation (and/or cetuximab) improved overall survival. The sobering answer was no: the survival rate was
lower in the high-dose RT arm, and the addition of cetuximab
made no difference.1
The survival result of this randomized clinical trial (RCT)
was not as hypothesized from the favorable phase 2 clinical
trial data supporting the high-dose RT approach.2-4 While there
were more grade 5 treatment-related toxic effects in the highdose RT arm (8 vs 3 patients), this difference was not significant. Based on the clinician-reported toxic effect scores, the
only significant difference between the 2 arms was severe, albeit transient, esophagitis, which was higher in the 74-Gy arm
(21% vs 7%; P < .001).
Patient-reported outcomes are an important secondary end
point of this study. Quality of life (QOL) data were collected
prospectively via a validated lung cancer instrument, the Functional Assessment of Cancer Therapy (FACT)–Trial Outcome Index (TOI),5,6 which has been associated with clinically meaningful changes in patients with lung cancer.7 The primary QOL
hypothesis predicted a clinically meaningful decline (CMD) in
the FACT Lung Cancer Subscale (LCS) in the high-dose RT arm
at 3 months. The prognostic value of QOL in predicting survival was also studied, as was the potential impact of irradiation technique on QOL.

Methods
Study Design and Patients
The methodology for the RCT is described in detail in the clinical outcomes article.1 Briefly, the study used a 2 × 2 factorial
design with RT dose as one factor and cetuximab as the other,
stratified by RT technique, Zubrod performance status, use of
positron emission tomography during staging, and histology,
with a primary end point of overall survival. The study is registered with clinicaltrials.gov (NCT00533949). The institutional
review board of each participating institution reviewed and
approved the study protocol. All patients read and signed an
informed consent document. Concurrent chemoradiation
included weekly paclitaxel (45 mg/m2) and carboplatin (AUC,
2) followed by 2 cycles of consolidation chemotherapy. In
addition to the RT dose randomization (60 Gy vs 74 Gy),
patients randomized to cetuximab received a 400-mg/m2
loading dose on day 1 followed by weekly doses of 250 mg
/m2. For the analysis, race was self-reported by the patients
(using options defined by the investigators).

Health-Related QOL Measures
Quality of life was measured via the use of FACT-TOI, a validated component of the FACT-Lung (FACT-L) QOL instrument, which can be completed in less than 10 minutes and has
360

At a Glance
• The primary hypothesis predicted a clinically meaningful decline
in quality of life (QOL) in the high-dose radiation therapy (RT)
arm at 3 months of a randomized RT dose-escalation study of
stage III non–small-cell lung cancer.
• More patients in the high-dose (74-Gy) than in the standard-dose
(60-Gy) RT arm had clinically meaningful decline in QOL at 3
months (45% vs 30%; P = .02).
• Despite few differences in clinician-reported toxic effects
between arms, QOL analysis showed a clinically meaningful
decline in QOL in the high-dose RT arm at 3 months.

been extensively used in patients with lung cancer.5,6 The
FACT-TOI includes the Physical Well Being (PWB), the Functional Well Being (FWB), and the Lung Cancer Subscale (LCS)
measurements. Importantly, the FACT-TOI has been associated with clinically meaningful changes in patients with lung
cancer.7 The LCS consists of 9 items involving common lung
cancer symptoms, such as shortness of breath, weight loss,
coughing, and loss of appetite. All items are rated on a 5-point
Likert scale, from 0 (not at all) to 4 (very much). Cella et al7
have reported minimal clinically meaningful changes of 2
points or more for PWB, FWB, and LCS or 5 points or more for
TOI, criteria used in the present analysis.
The primary QOL hypothesis predicted a CMD in LCS in
the high-dose RT arm at 3 months. While radiation dose escalation was hypothesized to yield greater tumor cell kill, it may
also increase the toxic effects to normal tissue, thereby leading to a decrease in QOL. The measurements for the present
QOL analysis were taken at baseline (pretreatment), during the
last week of chemoradiation, and at 3 and 12 months from the
start of treatment. The patients were given the QOL instrument to be completed in the clinic at the specified time points.
If the patient did not come into the clinic, the questionnaire
was mailed to the patient.

Statistical Considerations
All registered patients were offered the opportunity to prospectively participate in the QOL study. The differences in QOL
scores (ie, FACT-TOI and its subscales) between baseline and
each follow-up evaluation were computed for each individual patient and then classified as a clinically meaningful
change or not, based on the criteria defined by Cella et al.7
Completion of the QOL assessments and reasons for noncompliance were reported. The effects of missing QOL measurements were systematically assessed by determining whether
patients with and without QOL data at each time point had similar distributions in the treatment arms, pretreatment characteristics, and overall survival; we also used interaction tests
to determine if the associations between treatment arms and
pretreatment characteristics or treatment arms and overall survival differed between patients with and without QOL data.
Descriptive statistics were presented for both categorical
and continuous variables. Differences between study groups
in pretreatment characteristics and QOL scores were assessed by using the χ2 test or the Fisher exact test for categorical variables and t tests or Wilcoxon rank sum tests.8 Effect sizes
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of QOL score changes between study groups were calculated
based on the Cohen d statistic.9 Differences between study
groups in CMD were assessed univariately using CochranMantel-Haenszel statistics (stratified by cetuximab usage)
and multivariately using logistic regression adjusting
for important pretreatment characteristics and dosimetric
parameters.
The Kaplan-Meier method was used to estimate rates of
overall survival (duration from randomization to death or to
last follow-up), and the log-rank test was used to compare these
estimates between groups.10 Cox proportional hazards models were used to quantify the prognostic value of baseline QOL
on overall survival after adjusting for RT level, cetuximab usage, and potential prognostic factors. To address potential guarantee-time bias,11 a conditional landmark analysis in conjunction with Cox proportional hazard models was used to evaluate
the prognostic value of CMD on conditional survival after adjusting for potential confounding variables. In this landmark
analysis, patients whose last follow-up was prior to the landmark time (eg, 3 months) were excluded from the analysis, and
the change at the prespecified landmark time (eg, 3 months)
was used as a predictor for survival conditional on surviving
the landmark time.12 A 2-sided significance level of .05 was
used throughout. Of note, the extent of QOL decline was analyzed based on predefined and independently validated clinically meaningful changes, already representing moderate
effects.7 All analyses were performed with SAS software, version 9.2 (SAS Institute Inc).

Results
Between November 2007 and June 2011, the end of the RTlevel randomization, the trial accrued 464 patients, of whom
424 were ultimately eligible for analysis. Figure 1 is a QOL Consolidated Standards of Reporting Trials (CONSORT) diagram
detailing the level of QOL participation at each time point.
Briefly, 360 participants (85%) consented to QOL evaluation,
of whom 313 (87%) completed the baseline QOL form (FACTTOI). Other than patient attrition (as expected), the main reason for missing data was institutional error (QOL form not given
or collected on time).
Table 1 summarizes the pretreatment characteristics for patients consenting to QOL evaluation by RT dose arm and RT
technique. For both RT dose arms and techniques, approximately 60% of patients were male and 40% female. There were
no significant differences between RT dose arms in demographics (including race), and there was equal use of cetuximab. Similarly, among patients who completed QOL assessments at subsequent time points, there were no significant
differences in any demographics or treatment factors between RT dose arms, except for more stage IIIB patients in the
high-dose arm at the end of chemoradiation therapy. There
were no significant differences in treatment arms, pretreatment characteristics, or survival rates between patients with
completed or missing QOL assessments at baseline. Moreover, there were no significant differences in the associations
between treatment arms and pretreatment characteristics, or
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treatment arms and survival between patients with or without QOL, suggesting that the data are missing at random.13
Table 2 summarizes the baseline LCS and FACT-TOI scores
and the changes over time at 3 and 12 months by radiation dose
and technique. (The results at the end of chemoradiation are
provided in eTable 1 in the Supplement, and the FWB and PWB
data are listed in eTable 2 in the Supplement.) There were no
significant differences in baseline QOL scores by RT dose or
technique (Table 2).
At the end of concurrent chemoradiation therapy, 173 (55%)
of the 313 patients with baseline QOL data completed the next
QOL assessment, with similar completion rates in the 60-Gy
and 74-Gy arms (57% vs 53%; P = .57). The decline in LCS at
the end of chemoradiation tended to be higher in the 74-Gy
arm, although not significantly so (33% vs 46%; P = .08; effect size [ES], −0.31). Compared with the end of chemoradiation measurement, more patients (219, or 70% of those with
baseline QOL data) completed QOL assessment at 3 months after baseline (the primary QOL time point), and 9 patients (3%)
died prior to this assessment. The proportion of completed
forms at 3 months was also similar between RT dose arms (67%
vs 73%; P = .31). The proportion of patients who reported a CMD
in the LCS was significantly higher in the 74-Gy arm than in
the 60-Gy arm at 3 months (45% vs 30%; P = .02), corresponding to a moderate ES of 0.38 (Table 2 and Figure 2). At 12 months
after baseline, 73 patients (23%) of the 313 who completed the
baseline QOL were not alive; 137 patients (44%) completed QOL
assessment, corresponding to a completion rate of 57% among
living patients. The proportion of completed forms at 12 months
was again similar between the RT dose arms (54% vs 61%;
P = .33). The decline in QOL at 12 months between the RT dose
arms was similar for FACT-TOI and for all the subscales. These
results continued to hold in multivariate analysis after adjusting for potential confounding variables, including cetuximab
usage, RT dosimetric factors, treatment parameters, and baseline characteristics.
Within an exploratory analysis (see eTable 3 and eTable 4
in the Supplement), several dosimetric factors appeared to be
significantly associated with CMD in QOL in both univariate
and multivariate logistic regression models as follows: lung V20
(the percentage of the lung receiving >20 Gy) was associated
with CMD in PWB, FWB and TOI at end of chemoradiation;
esophagus V60 (the percentage of the esophagus receiving >60
Gy) and planning target volume (PTV) were associated with
CMD in PWB and TOI at 3 months. Heart V5 (the percentage
of the heart receiving >5 Gy) was associated with CMD in FWB
at 12 months. The variations in radiation doses (between intensity-modulated RT [IMRT] and 3-dimensional conformal RT
[3D-CRT]) for the lung, esophagus, and heart were not significantly different among patients completing the QOL forms at
baseline (see eTable 4 in the Supplement) or any subsequent
time point. Of note, conditional survival of patients with early
CMD in the LCS at the end of chemoradiation was nonsignificantly lower than those without (18-month survival rates, 54%
vs 71%; log-rank P = .27).
Intensity-modulated RT was used in 44% and 46% of patients with baseline QOL data in the 60-Gy and 74-Gy arms, respectively (P = .72; Table 1). Of note, this study was stratified,
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Figure 1. Study Participants’ Enrollment and Progress Flowchart
424 Assessed
313
for eligibility

360 Consented to participate in
PRO/QOL component

Baseline
186 Randomized to standard dose (60 Gy)
10 Data not received
15 Not completed
2 Patients refused for other reason
1 Institutional error
3 Unknown or other reason
9 Completed after start of treatment
161 With baseline QOLA

Baseline
174 Randomized to high dose (74 Gy)
4 Data not received
18 Not completed
1 Patient refused for other reason
1 Institutional error
3 Unknown or other reason
13 Completed after start of treatment
152 With baseline QOLA

End of Chemoradiation
46 Data not received
3 Died prior to assessment
40 Not completed
1 Patient refused due to illness
3 Patients refused for other reason
14 Institutional error
3 Unknown or other reason
19 Completed too early or too late
97 With end-of-chemoradiation QOLA

End of Chemoradiation
40 Data not received
4 Died prior to assessment
43 Not completed
2 Patients refused due to illness
2 Patients refused for other reason
17 Institutional error
10 Unknown or other reason
12 Completed too early or too late
87 With end-of-chemoradiation QOLA

92 With both baseline and
end-of-chemoradiation QOLA

81 With both baseline and
end-of-chemoradiation QOLA

3-Month Follow-up
Data not received
Died prior to assessment
Withdrew consent to further QOL assessments
Not completed
2 Patients refused due to illness
2 Patients refused for other reason
12 Institutional error
5 Unknown or other reason
10 Completed too early or too late
118 With 3-month QOLA

3-Month Follow-up
24 Data not received
5 Died prior to assessment
39 Not completed
1 Patient refused due to illness
3 Patients refused for other reason
14 Institutional error
6 Unknown or other reason
15 Completed too early or too late
118 With 3-month QOLA

16
8
1
31

108 With both baseline and 3-month QOLA

111 With both baseline and 3-month QOLA

12-Month Follow-up
Data not received
Died prior to assessment
Withdrew consent to further QOL assessments
Not completed
3 Patients refused due to illness
5 Patients refused for other reason
14 Institutional error
15 Unknown or other reason
7 Completed too early or too late
73 With 12-month QOLA

12-Month Follow-up
Data not received
Died prior to assessment
Withdrew consent to further QOL assessments
Not completed
2 Patients refused due to illness
13 Patients refused for other reason
23 Institutional error
14 Unknown or other reason
11 Completed too early or too late
75 With 12-month QOLA
13
34
1
63

8
48
1
44

70 With both baseline and 12-month QOLA

67 With both baseline and 12-month QOLA

PRO indicates patient-reported outcome; QOL, quality of life; QOLA, QOL assessment.

but not randomized, by radiation technology (IMRT vs 3DCRT). Overall there were no significant differences in patient
demographics or treatment factors between IMRT and 3DCRT (Table 1), with the following exceptions: significantly more
patients with higher-stage disease (43% vs 31% stage IIIB;
P = .04) and larger PTVs (median 509 vs 409 mL; P < .001) were
treated using IMRT than 3D-CRT. When analyzing results by
radiation technique (Table 2 and Figure 2), we found that patients who received IMRT had significantly less CMD in LCS
362

at 12 months than those treated with 3D-CRT (21% vs 46%;
P = .003; ES, 0.37). Similar results at 12 months were found with
FACT-TOI (57% vs 36%; P = .01; ES, 0.34). Radiation technique remained significantly associated with CMDs in LCS
(odds ratio [OR], 0.29 [95% CI, 0.13-0.69]; P = .01) and TOI (OR,
0.42 [95% 0.20-0.90]; P = .03) at 12 months in multivariate
logistic regression models.
Beyond RT dose level, baseline QOL (PWB, FWB, and
FACT-TOI) was also significantly associated with survival
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Table 1. Characteristics by RT Dose and Type for Patients Consenting to QOL Assessmenta
RT Dose
Characteristic

60 Gy
(n = 186)

RT Type
74 Gy
(n = 174)

3D-CRT
(n = 198)

IMRT
(n = 162)

Total
(n = 360)

RT dose
Standard, 60 Gy

NA

NA

104 (52.5)

82 (50.6)

186 (51.7)

High, 74 Gy

NA

NA

94 (47.5)

80 (49.4)

174 (48.3)

RT type
3D-CRT
IMRT

104 (55.9)

94 (54.0)

NA

NA

198 (55.0)

82 (44.1)

80 (46.0)

NA

NA

162 (45.0)

85 (45.7)

81 (46.6)

91 (46.0)

75 (46.3)

166 (46.1)

101 (54.3)

93 (53.4)

107 (54.0)

87 (53.7)

194 (53.9)

Cetuximab
Cetuximab
No cetuximab
Age, median (range), y

64 (38-83)

64 (41-83)

64 (38-82)

64 (38-83)

64 (38-83)

Sex
Male
Female

110 (59.1)

103 (59.2)

117 (59.1)

96 (59.3)

213 (59.2)

76 (40.9)

71 (40.8)

81 (40.9)

66 (40.7)

147 (40.8)

Race/ethnicity
American Indian or Alaskan native

1 (0.5)

1 (0.6)

2 (1.0)

0

2 (0.6)

Asian

3 (1.6)

5 (2.9)

3 (1.5)

5 (3.1)

8 (2.2)

Black or African American

16 (8.6)

17 (9.8)

19 (9.6)

14 (8.6)

33 (9.2)

Native Hawaiian or other
Pacific Islander

1 (0.5)

White

0

1 (0.5)

0

164 (88.2)

150 (86.2)

171 (86.4)

1 (0.5)

1 (0.6)

2 (1.0)

0

114 (61.3)

109 (62.6)

123 (62.1)

100 (61.7)

223 (61.9)

1

72 (38.7)

65 (37.4)

75 (37.9)

62 (38.3)

137 (38.1)

Unknown

143 (88.3)

1 (0.3)

0

314 (87.2)
2 (0.1)

Zubrod PS

PET staging
No

18 (9.7)

20 (11.5)

25 (12.6)

13 (8.0)

38 (10.6)

Yes

168 (90.3)

154 (88.5)

173 (87.4)

149 (92.0)

322 (89.4)

Squamous cell

81 (43.5)

82 (47.1)

96 (48.5)

67 (41.4)

163 (45.3)

Adenocarcinoma

73 (39.2)

59 (33.9)

69 (34.8)

63 (38.9)

132 (36.7)

3 (1.6)

6 (3.4)

6 (3.0)

3 (1.9)

9 (2.5)

29 (15.6)

27 (15.5)

27 (13.6)

29 (17.9)

56 (15.6)

IIIA/N2

123 (66.1)

108 (62.1)

137 (69.2)b

94 (58.0)b

231 (64.2)

IIIB/N3

63 (33.9)

66 (37.9)

61 (30.8)

68 (42.0)

Histology

Large cell
NOS
AJCC stage

PTV
Median (range), mL
Educational level

(n = 149)

(n = 174)

(n = 130)

(n = 304)

447.3
(99.0-1851.2)

467.5
(100.6-1836.4)

409.2b
(99.0-1836.4)

508.3b
(103.3-1851.2)

454.8
(99.0-1851.2)

(n = 168)

(n = 162)

(n = 186)

(n = 144)

(n = 330)

<High school

25 (14.9)

21 (13.0)

29 (15.6)

17 (11.8)

46 (13.9)

High school

77 (45.8)

65 (40.1)

77 (41.4)

65 (45.1)

142 (43.0)

>High school
Marital status
Married or partnered
Single, widowed, or divorced

66 (39.3)

76 (46.9)

80 (43.0)

62 (43.1)

(n = 170)

(n = 191)

118 (65.6)

117 (68.8)

123 (64.4)

112 (70.4)

235 (67.1)

62 (34.4)

53 (31.2)

68 (35.6)

47 (29.6)

115 (32.9)

b

(n = 159)

142 (43.0)

(n = 180)

Abbreviations: AJCC, American Joint Committee on Cancer;
IMRT, intensity-modulated RT; NA, not applicable; NOS, not otherwise
specified; PET, positron emission tomography; PS, performance status;
PTV, planning target volume; QOL, quality of life; RT, radiation therapy;
3D-CRT, 3-dimensional conformal RT.
a

129 (35.8)

(n = 155)

(n = 350)

The differences between 3D-CRT and IMRT for these factors (AJCC stage and
PTV volume) were significantly different (P ⱕ .03), but all other comparisons
were not significantly different (P > .10).

Unless otherwise noted, data are reported as number (percentage) of study
participants.
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Table 2. FACT-LCS and FACT-TOI Scores Over Time by RT Dose and Typea
FACT Score

Baseline

RT Dose, Gy

60

LCS

Change at 3 Months
74

(n = 161)

Mean (SD)

(n = 152)

18.7 (5.1)

Median (range)

19.0
(3.0 to 28.0)

Effect sizeb

NA

P valuec

60
(n = 108)

19.5 (4.9)
20.0
(3.0 to 28.0)

0.5 (5.8)
0.0
(−14.0 to 17.0)

(n = 111)
−1.7 (5.9)
−2.0
(−15.0 to 15.0)

−0.381
.22

60
(n = 70)
−0.4 (5.0)
0.0
(−11.0 to 15.0)

74
(n = 67)
−0.2 (5.1)
−1.0
(−13.0 to 12.0)

0.035

.02

.94

No decline, No. (%)

NA

NA

75 (70.1)

60 (55.0)

45 (65.2)

41 (61.2)

Decline, No. (%)

NA

NA

32 (29.9)

49 (45.0)

24 (34.8)

26 (38.8)

P valuec

NA

TOI

.02

(n = 161)

Mean (SD)

(n = 152)

60.8 (13.4)

Median (range)

62.0
(25.6 to 83.0)

Effect sizeb

NA

P valuec

(n = 105)

61.4 (13.7)
63.0
(23.0 to 84.0)

−6.7 (16.0)
−8.6
(−47.0 to 38.0)

.62
(n = 108)
−9.8 (15.6)
−8.4
(−47.0 to 20.0)

−0.198
.69

(n = 69)
−3.7 (13.3)
−3.0
(−30.2 to 28.0)

(n = 67)
−4.9 (14.2)
−5.3
(−50.0 to 26.0)

−0.090

.39

.79

No decline, No. (%)

NA

NA

46 (43.8)

46 (42.6)

36 (52.2)

33 (49.3)

Decline, No. (%)

NA

NA

59 (56.2)

62 (57.4)

33 (47.8)

34 (50.7)

P valuec

.89

.72

RT Type

3D-CRT

IMRT

3D-CRT

IMRT

3D-CRT

IMRT

LCS

(n = 179)

(n = 134)

(n = 129)

(n = 87)

(n = 84)

(n = 52)

Mean (SD)

19.1 (5.0)

Median (range)

20.0
(3.0 to 28.0)

Effect sizeb

NA

P valuec

19.0 (5.0)
19.0
(3.0 to 28.0)

−1.1 (6.1)
−2.0
(−14.0 to 15.0)

0.2 (5.6)
0.0
(−15.0 to 17.0)

0.214
.85

−1.0 (5.0)
−2.0
(−11.0 to 12.0)

0.8 (4.9)
1.0
(−13.0 to 15.0)

0.366

.04

.02

No decline, No. (%)

NA

NA

74 (57.4)

61 (70.1)

45 (53.6)

41 (78.8)

Decline, No. (%)

NA

NA

55 (42.6)

26 (29.9)

39 (46.4)

11 (21.2)

P valuec

NA

TOI

.05

(n = 179)

Mean (SD)

(n = 134)

61.3 (13.7)

Median (range)

62.0
(23.0 to 83.0)

Effect sizeb

NA

P valuec

(n = 127)

60.9 (13.3)
63.0
(31.0 to 84.0)

−9.0 (15.6)
−8.6
(−47.0 to 31.0)

.003
(n = 86)
−7.2 (16.2)
−8.3
(−45.0 to 38.0)

0.114
.70

(n = 84)
−6.0 (13.0)
−7.8
(−34.0 to 28.0)

(n = 52)
−1.5 (14.6)
−2.0
(−50.0 to 28.0)

0.336

.45

.02

No decline, No. (%)

NA

NA

54 (42.5)

38 (44.2)

36 (42.9)

33 (63.5)

Decline, No. (%)

NA

NA

73 (57.5)

48 (55.8)

48 (57.1)

19 (36.5)

P valuec

NA

.82

.01

Abbreviations: FACT, Functional Assessment of Cancer Therapy; LCS, Lung
Cancer Subscale; RT, radiation therapy; TOI, Trial Outcome Index.

b

Effect sizes between groups were calculated as the difference in mean score
changes divided by the pooled SD of the score changes.

a

c

P values for continuous data are from a t test; P values from categorical data
are from a χ2 test; all P values are 2 sided.

Analyses were limited to patients with baseline and relevant follow-up FACT
forms; change is calculated by subtracting baseline from follow-up score; a
positive change indicates an improvement in function, and a negative change
indicates a decrease in function.

separately in univariate and multivariate Cox regression
models. Table 3 summarizes a multivariate Cox proportional
hazard analysis between baseline FACT-TOI (continuous) and
survival, with adjustment for cetuximab use, PTV, and heart
V5. Every 10 points higher on the FACT-TOI at baseline (for a
given patient compared with another) corresponded to a 10%
decreased risk of death (hazard ratio, 0.901; P = .046). Other
significant variables on multivariate analysis included PTV
and heart V5.
364

Change at 12 Months
74

Discussion
Despite few differences in clinician-reported toxic effects
between RT dose arms, the patient-reported outcomes clearly
demonstrated a clinically meaningful decline (CMD) in QOL
on the high-dose radiation arm at 3 months, confirming the
primary QOL hypothesis. Prior studies have demonstrated a
disconnect between the patient and clinician perspectives;
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clinicians often underestimate the level of symptom
burden.14,15 The only clinically relevant clinician-based toxic
effect found to be significantly different between RT dose
arms was severe esophagitis. However, while the rate of
severe esophagitis at 3 months in the high-dose arm was only
21%, more than 50% of patients reported a CMD in FACT-TOI
at 3 months.
Interestingly, in the RTOG 0617 clinical outcomes report,1
the significant factors associated with survival on multivariate analysis were RT dose level, PTV, heart dose, and severe
esophagitis. When incorporating QOL into the model, we
found that baseline QOL (FACT-TOI), rather than esophagitis,
was significantly associated with survival, in addition to RT
dose level, PTV, and heart dose (Table 3). Prior studies have
shown that QOL is significantly associated with survival in
lung cancer and other cancers.16,17 In this study, every 10
points higher in the QOL (FACT-TOI) score at baseline (for a
given patient compared with another) corresponded to a 10%
decreased risk of death. Similarly, in another locally
advanced NSCLC randomized trial,16 a 10-point higher baseline global QOL score corresponded to a decrease in the hazFigure 2. Decline in Patient-Reported Quality of Life by Type and
Dose of RT
3 Months

12 Months

Decline in FACT-LCS, %

80

P =.02

P =.003
P =.05

P =.62

60 Gy 74 Gy

3D-CRT IMRT

60 Gy 74 Gy

3D-CRT IMRT

RT Dose

RT Type

RT Dose

RT Type

60

40

20

0

FACT-LCS indicates Functional Assessment of Cancer Therapy–Lung Cancer
Subscale; IMRT, intensity-modulated RT; RT, radiation therapy;
3D-CRT, 3-dimensional conformal RT.

ard of death by 10%. This clinically relevant finding suggests
that QOL may be considered a stratification factor in future
locally advanced NSCLC trials.
This analysis raises a question about an association between early decline in QOL in the high-dose radiation arm and
the survival decrement found in this study. Of note, patients
with a CMD in LCS early on (at the completion of chemoradiation) were found to have a nonsignificantly lower 18-month
survival (54%) compared with those without CMD in LCS (71%).
In another trial, a decline in LCS was significantly associated
with lower survival in lung cancer.18
Other important factors to consider include tumor volume and heart dose. Tumor volume is a well-known negative prognostic factor for survival.19 Heart dose also appears
to be a factor that may partly explain the decline in overall
survival and poorer QOL in the high-dose arm. From a dosimetric perspective, lung V20 and esophagus V60 correlated
with CMD in QOL at early time points (within 3 months),
possibly due to the acute radiation effects of inflammation
in these organs. Only heart V5 significantly correlated with
CMD with longer follow-up (at 12 months), suggesting that
chronic radiation cardiac effects may be clinically relevant
and deserve further study. Thus far, no single covariate
explains the large survival gap between the 2 RT dose arms,
suggesting that the answer to this complex issue is likely
multifactorial.
The main limitation of this analysis, which affects many
QOL studies, is the issue of missing data.20,21 In this study,
approximately 70% of patients completed QOL assessment at
3 months, and 57% of living patients completed QOL assessment at 12 months. While these QOL completion rates are
reasonable for a locally advanced lung cancer trial,22,23 it
raises the possibility that there could be nonrandom factors
underlying the missing QOL data. Although matched at baseline, patients who were sicker or who had poorer QOL during
the study period (or who died at earlier time points) could
disproportionately have not completed the QOL tools. However, in this study, there were no significant differences in
the associations between treatment arms and pretreatment
characteristics or treatment arms and survival between
patients with or without QOL data. Moreover, among patients
who completed QOL assessment, there were essentially no
significant differences in demographics or treatment factors

Table 3. Multivariate Cox Model of Overall Survivala
Covariate

Comparison

Radiation level

High dose vs standard dose (RL)

Cetuximab assignment

No cetuximab vs cetuximab (RL)

PTV

Continuous

High-Dose
Dead/Totalc

HR (95 CI)

P Valued

97/155

106/147

1.42 (1.07-1.87)

.01

90/133

133/169

0.90 (0.68-1.19)

.44

1.001 (1.000-1.001)

.04

Standard-Dose
Dead/Totalb

203/302

Heart V5

Continuous

203/302

1.007 (1.002-1.012)

.01

FACT-TOIe

Continuous

203/302

0.901 (0.813-0.998)

.046

Abbreviations: FACT, Functional Assessment of Cancer Therapy;
heart V5, volume of heart receiving 5 Gy or more radiation; HR, hazard ratio;
PTV, planning target volume; RL, reference level; TOI, Trial Outcome Index.
a

Underlying multivariate model developed in the primary end point analysis.1

b

For standard-dose group or cetuximab group.

c

For high-dose group or no cetuximab group.

d

Two-sided P value.

e

Baseline FACT-TOI, every 10 points.
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(including use of cetuximab) between arms at any QOL
assessment time.
Other than patient attrition (as is to be expected in a
lung cancer trial), the main reason for missing data was
institutional error (such as the QOL form not being administered or collected on time). To reduce missing QOL
data, RTOG has tested an electronic web-based strategy.24
This novel approach almost eliminated institutional error
as the cause of missing data by using real time email
reminders.
A strength of this QOL analysis is that the results were
not simply based on differences that were statistically significant but, more importantly, on changes that were clinically meaningful using a validated QOL instrument. The
results emphasize the importance of having a predefined
clinically meaningful change by which to interpret QOL
findings.
As QOL assessment provides data directly from the
patient perspective, it provides an opportunity to explore
potential strategies that might not have otherwise been
appreciated. While RTOG 0617 was stratified, but not randomized, to compare IMRT with 3D-CRT, less CMD in the LCS
at 1 year was associated with the use of IMRT (P = .003),
despite the fact that IMRT was used to treat patients with
higher stages of disease and larger tumor volumes. Retro-
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spective studies have suggested dosimetric and/or clinical
benefits of IMRT (over 3D-CRT) in stage III NSCLC.25-27 When
performed carefully with motion control and image-guided
RT, as in this study, IMRT facilitates integrated RT dose painting to tumor regions while minimizing the dose delivered to
surrounding normal tissues. As previously reported,1 overall,
the use of IMRT vs 3D-CRT did not affect survival in this
study, and a detailed analysis of this issue will be published
separately. To our knowledge, RTOG 0617 is the largest prospective study incorporating QOL as an end point in patients
treated with modern techniques of IMRT or 3D-CRT for stage
III NSCLC.

Conclusions
The QOL analysis of RTOG 0617 demonstrates that baseline
QOL was significantly associated with survival on multivariate analysis. This analysis suggests that improved RT treatment techniques may enhance the therapeutic window for patients with lung cancer. Finally, despite few differences in
clinician-reported toxic effects between RT dose arms, the patient-reported outcomes demonstrated significantly worse QOL
in the high-dose arm at 3 months, confirming the primary QOL
hypothesis.
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Editor's Note

The Importance of Quality of Life Assessment
Charles R. Thomas Jr, MD, PhD

Dose escalation of an antineoplastic modality such as radiotherapy (RT) may result in an increased therapeutic ratio with
the use of effective strategies to mitigate normal tissue toxic
effects. Successful execution of dose escalation using
Related article page 359
external beam RT (EBRT) approaches has yielded unintended outcomes.1,2 While increased disease control and survival are a focus of such strategies to increase the therapeutic
ratio, quality of life (QOL), as measured by appropriate patientrelated outcomes tools, are nearly as important. To that end,
Movsas et al,3 in this issue of JAMA Oncology, document that
an attempt to deliver nearly a quarter higher total dose (74 Gy
vs 60 Gy) of EBRT given concomitantly with a platinumtaxane doublet for locally advanced non–small-cell lung cancer (LA-NSCLC) results in a clinically meaningful decrement
in QOL at 3 months.3
However, the Radiation Therapy Oncology Group 0617
trial is not the definitive treatise regarding the RT dose-

escalation question for LA-NSCLC. The QOL assessments, as
well as the survival results, likely were influenced by numerous factors that are difficult to control for in a multi-institutional, cooperative group clinical trial setting. Emerging
data on molecular signatures that may predict radiosensitivity and/or radioresistance of tumor, as well as normal tissues, may be helpful in future assessment of baseline patient
characteristics for those enrolled in prospective, large-scale
cancer clinical trials of RT-based treatment. Moreover, not all
modes of potential RT delivery and dose escalation are
equal. Currently, radiation oncologists see patients on a
weekly basis and basically assess symptoms as a “snapshot
in time.” This is fraught with recall bias and other factors
that contribute to a diminished appreciation of real-time
patient-related outcomes, which should ideally be recorded
on a continuous 24/7 basis to assess QOL during treatment.
Movsas and colleagues are to be congratulated for executing
a trial that will help in the design of next-generation QOL
trials for LA-NSCLC.
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